Exact Sciences Corporation

And welcome to the Exact Sciences fourth quarter 2023 earnings call. Please be advised that this call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Please be advised, we ask you to limit your request to one question. Thank you. I would now like to turn the conference over to Mr. Nate Harrell, Vice President of Investor Relations. You may begin your conference.

Thanks, Jeannie. Thank you for joining us for ExactScience's fourth quarter 2023 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, and Brian Berenik, our General Manager of Precision Oncology, will also be available for questions. Exact Sciences issued a news release earlier this afternoon detailing our fourth quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risk and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

Thanks, Nate. 2023 was another record-breaking year for Exact Sciences, and our fourth quarter results set the tone for an impactful year ahead. A special thanks to our team for testing a record number of people during the quarter with our established brands, Cologuard, Oncotype DX, and Prevention Genetics. We've built an unrivaled platform that will allow us to achieve our purpose to help eradicate cancer. We're hosting today's call from our San Diego R&D Center. Our talented scientists are harnessing the power of DNA, RNA, and proteins. They're developing a range of new tests. that will change how cancer is diagnosed and treated. We're set to gain momentum as we bring these new tests to physicians and patients at regular intervals over the next few years. Highlights in 2023 include testing a record 4.1 million patients for cancer and rare diseases, growing core revenue by 24% to 2.5 billion. Improving adjusted EBITDA, $362 million year-over-year. Turning free cash flow positive. Submitting next-generation Cologuard for FDA approval. Launching Oncotype DX in Japan on a reimbursed basis. Accelerating our molecular residual disease, or MRD, program. Launching OncoExtra, our solid tumor therapy selection test, and adding OncoLiquid, our liquid therapy selection test. and advancing our multi-cancer early detection. The Exact Sciences team is laser-focused on five things this year. Further embedding Cologuard as standard of care, increasing OncotypeDS adoption internationally, advancing key pipeline programs, deepening relationships with health systems, and delivering experiences that patients and providers love. Jeff will now focus on our financial results and our outlook for 2024.